RIVIVE (Naloxone Hydrochloride) Patent Expiration, LOE Window & CMS Spending

RIVIVE (Naloxone Hydrochloride) by Harm Reduction Therapeutics: FDA Orange Book core substance LOE 2032-05-11, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHarm Reduction Therapeutics
FDA Application & PathwayN217722 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-05-11
Last Listed Patent or Exclusivity Date2032-05-11
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel